Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This study is currently recruiting participants.
Verified March 2013 by National Cancer Institute (NCI)
Study NCT00588991
Information provided by National Cancer Institute (NCI)
First Received on December 20, 2007.
Last Updated on March 28, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
